Subscribe
millefloreimages-istockphoto-com-breast-cancer-
MillefloreImages / iStockphoto.com
31 July 2017Americas

AstraZeneca and Merck enter $8.5bn cancer therapy collaboration

AstraZeneca has entered into an oncology collaboration with Merck, under which the companies will co-develop AstraZeneca’s Lynparza (olaparib).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
AstraZeneca and Daiichi Sankyo to jointly develop another new cancer treatment
30 July 2020   Biopharmaceutical company AstraZeneca has struck a deal with Japanese pharmaceutical company Daiichi Sankyo to jointly develop and market a new medicine to treat lung, breast and other cancers.
Americas
Italian research organisation extends collaboration with Merck & Co
5 September 2018   Italy-based research organisation IRBM has signed a new agreement with Merck & Co in the peptides therapeutics area, extending the parties’ long-standing collaboration.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Big Pharma
AstraZeneca and Daiichi Sankyo to jointly develop another new cancer treatment
30 July 2020   Biopharmaceutical company AstraZeneca has struck a deal with Japanese pharmaceutical company Daiichi Sankyo to jointly develop and market a new medicine to treat lung, breast and other cancers.
Americas
Italian research organisation extends collaboration with Merck & Co
5 September 2018   Italy-based research organisation IRBM has signed a new agreement with Merck & Co in the peptides therapeutics area, extending the parties’ long-standing collaboration.

More on this story

Big Pharma
AstraZeneca and Daiichi Sankyo to jointly develop another new cancer treatment
30 July 2020   Biopharmaceutical company AstraZeneca has struck a deal with Japanese pharmaceutical company Daiichi Sankyo to jointly develop and market a new medicine to treat lung, breast and other cancers.
Americas
Italian research organisation extends collaboration with Merck & Co
5 September 2018   Italy-based research organisation IRBM has signed a new agreement with Merck & Co in the peptides therapeutics area, extending the parties’ long-standing collaboration.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler